Drugs / B43-Genistein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004858 | Mar 2000 → ? | leukemia, lymphoma | Parker Hughes Cancer Center | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | B43-Genistein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004858 ↗ |
| Action | Inhibit | “the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein” PMID 10632319 ↗ Dec 1999 |
| Route | Intravenous | “Patients receive B43-genistein immunoconjugate IV over 1 hour” NCT00004858 ↗ |
| Target | CD19 | “the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein” PMID 10632319 ↗ Dec 1999 |